Literature DB >> 7200999

Penetration of amoxicillin, cefaclor, erythromycin-sulfisoxazole, and trimethoprim-sulfamethoxazole into the middle ear fluid of patients with chronic serous otitis media.

P J Krause, N J Owens, C H Nightingale, J J Klimek, W B Lehmann, R Quintiliani.   

Abstract

Penetration into the middle ear of four antibiotics commonly used in treatment of otitis media was studied by administering a single oral dose of amoxicillin, cefaclor, erythromycin-sulfisoxazole, or trimethoprim-sulfamethoxazole to 83 children with chronic serous otitis media. The antibiotic was given 15-240 min before the removal of middle ear fluid (MEF) by ventilation tubes inserted through the tympanic membrane. At the time MEF was obtained, a sample of blood was drawn from the patient, and concentrations of antibiotic in both specimens were assayed either microbiologically by a disk diffusion method or by high-pressure liquid chromatography. Amoxicillin had the highest ratio of mean peak concentration in MEF to minimal inhibitory concentration (MIC) for the three most common pathogens of otitis media (Streptococcus pneumoniae, ampicillin-sensitive Haemophilus influenzae, and Streptococcus pyogenes), whereas trimethoprim-sulfamethoxazole had the highest ratio of mean peak concentration in MEF to MIC for ampicillin-resistant Haemophilus influenzae.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7200999     DOI: 10.1093/infdis/145.6.815

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  26 in total

1.  Confidentiality of workers' medical records.

Authors:  Clifford S Amundson
Journal:  Can Fam Physician       Date:  1985-10       Impact factor: 3.275

2.  Loracarbef concentrations in middle ear fluid.

Authors:  H Kusmiesz; S Shelton; O Brown; S Manning; J D Nelson
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

Review 3.  Variations in amoxicillin pharmacokinetic/pharmacodynamic parameters may explain treatment failures in acute otitis media.

Authors:  Michael E Pichichero; Michael D Reed
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

4.  High dose amoxicillin: Rationale for use in otitis media treatment failures.

Authors: 
Journal:  Paediatr Child Health       Date:  1999-07       Impact factor: 2.253

5.  Penetration of ceftibuten into middle ear fluid.

Authors:  C Lin; P Kumari; R J Perrotta; B E Reidenberg
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

6.  Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model.

Authors:  D M Cappelletty; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

7.  Rationale behind high-dose amoxicillin therapy for acute otitis media due to penicillin-nonsusceptible pneumococci: support from in vitro pharmacodynamic studies.

Authors:  P D Lister; A Pong; S A Chartrand; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

8.  In vivo activity and pharmacodynamics of amoxicillin in combination with fosfomycin in fibrin clots infected with highly penicillin-resistant Streptococcus pneumoniae.

Authors:  P Chavanet; N Peyrard; A Pechinot; M Buisson; M Duong; C Neuwirth; A Kazmierczak; H Portier
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

9.  Amoxicillin concentrations in nasal secretions of patients with acute uncomplicated sinusitis and in paranasal sinus mucosa of patients with chronic sinusitis.

Authors:  G Kment; A Georgopoulos; W Ridl; J Mühlbacher
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

Review 10.  Antibiotic resistance in Haemophilus influenzae: mechanisms, clinical importance and consequences for therapy.

Authors:  R de Groot; G Dzoljic-Danilovic; B van Klingeren; W H Goessens; H J Neyens
Journal:  Eur J Pediatr       Date:  1991-06       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.